药物发现
计算生物学
药品
药理学
医学
生物
生物信息学
作者
Laure K. Case,Maximiliano F Presa,Saurabh Tata,Paige B Martin,Katelyn Tracey,Cat Lutz
出处
期刊:Journal of Immunology
[American Association of Immunologists]
日期:2024-05-01
卷期号:212 (1_Supplement): 0722_7837-0722_7837
标识
DOI:10.4049/jimmunol.212.supp.0722.7837
摘要
Abstract Systemic Lupus Erythematosus is a chronic autoimmune disease characterized by a broad spectrum of clinical manifestations. An important role of the type I interferon (IFN) pathway has been identified in SLE patients. No one mouse model completely recapitulates the complexity of the human disease. Nonetheless, mouse models of SLE have been instrumental in our understanding of the genetic and cellular requirements for SLE induction and represent a valuable resource for testing SLE therapies and drug candidates in vivo. Here we present preclinical reference data in a Trex1KO mouse model generated at the Jackson Laboratory using CRISPR technology. Trex1KO mice have a median survival of approximately 165 – 185 days. Body weight is significantly reduced in both male and female KO versus WT. Unlike NZBWF1/J and MRL/MpJ mouse models that develop lupus nephritis, the Trex1 KO develops dilated cardiomyopathy due to leukocyte infiltration and cardiomyocyte degeneration. Here we treated KO mice with anti-IFNα antibodies through 32 weeks of age. We observed a significant treatment effect on survival, reduction in leukocyte infiltration and degeneration of the heart, and percentage of T peripheral helper T cells in spleen. A mouse model recapitulating a role for type I IFN in disease pathogenesis has been lacking in the common models of SLE, and these data indicate that the Trex1KO model is relevant for the screening of targeted therapies of type I IFN and related pathways.
科研通智能强力驱动
Strongly Powered by AbleSci AI